Milestone Pharmaceuticals Files 8-K Report
Ticker: MIST · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1408443
Sentiment: neutral
Topics: filing, disclosure
TL;DR
Milestone Pharma filed an 8-K, likely containing financial updates and disclosures.
AI Summary
On February 25, 2025, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Milestone Pharmaceuticals Inc. has submitted required disclosures to the SEC, which may contain updates on financial status or other material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- February 25, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Milestone Pharmaceuticals Inc.
In which jurisdiction was Milestone Pharmaceuticals Inc. incorporated?
Milestone Pharmaceuticals Inc. was incorporated in Québec.
What is the principal executive office address of Milestone Pharmaceuticals Inc.?
The principal executive office address is 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, CA H4M 2X6.
What is the telephone number for Milestone Pharmaceuticals Inc.?
The telephone number for Milestone Pharmaceuticals Inc. is (514) 336-0444.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Milestone Pharmaceuticals Inc. (MIST).